Genetic profiling of CTCs via NGS could aid in classifying GBM subtypes for targeted patient selection into clinical trials and longitudinal monitoring. Discover how ANGLE can support your GBM trial protocols and patient recruitment strategies:

Selecting the right circulating tumour cell (CTC) enrichment platform for your glioblastoma (GBM) research is critical. The Parsortix PR1 system is optimised for this challenging disease and is supported by multiple peer reviewed publications.

#ANGLEplc Portrait® Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal and epithelial-to-mesenchymal transition circulating tumour cells (CTCs). Learn more about cancer progression: #LiquidBiopsy #CancerResearch #CTC

RT @OncologyCentral: How are liquid biopsies helping to advance the diagnosis and treatment of breast cancer? Check out our latest intervie….

RT @braintumourrsch: It's Glioblastoma Awareness Week! 💡. We’re shining a spotlight on the most aggressive type of brain tumour - glioblast….

Compelling evidence highlights ANGLE’s circulating tumour cell (CTC) enrichment platform, the Parsortix® system, the leading solution for CTC capture in glioblastoma (GBM) — one of the most challenging tumour types for liquid biopsy analysis. Discover why:

An exciting new study by Professor Nicola Aceto's team at ETH Zurich, Switzerland, published in Nature Genetics identifies circulating tumour cell (CTC) clusters as promising targets to stop the spread of cancer. Read the full publication here:

The Portrait®+ kit provides advanced immunofluorescent staining of circulating tumour cells (CTCs) including epithelial, mesenchymal, and EMT, from whole blood samples. The Portrait®+ CTC staining kit enables visualisation of CTCs from multiple cancer types.

Repeat tissue biopsies in GBM are often not feasible due to tumour location or patient status. ANGLE's Parsortix® technology enables the capture of CTCs from peripheral blood, offering a repeatable and minimally invasive option for comprehensive, multiomic profiling in GBM.

The #ANGLE team attended the #GenomicsEnglandResearchSummit2025 and were blown-away with the Genomics England’s continued mission to secure the UK’s position as the best place to discover, prove, and benefit from genomic innovations. #ANGLEplc #GenomicsEngland #CancerResearch

We are excited to welcome Corina Veronica Sasso from #Biomol, our Spanish distributor, to #ANGLE for two days of intensive product training and strengthening our global customer support network. Find your nearest ANGLE supplier:

We’re back from #EACR2025 and are energised by the work happening within #CancerResearch. Showing how #LiquidBiopsy is reshaping the way that cancer is understood, tracked, and treated; these conversations reinforce the collective drive behind the potential for patient impact.

Analysis of circulating tumour cells (CTC) from glioblastoma (GBM) patients enables minimally invasive protein and molecular biomarker analysis and longitudinal monitoring. ANGLE can help you incorporate this powerful tool into your GBM research study.

New posters available!.David Greaves and Megan Coates presented their posters during the Biomarkers in Tissue and Blood poster session at EACR2025 yesterday. View the posters in full:. For Research Use Only. Not for Use In Diagnostic Procedures.

The @EACRnews Annual Congress opened its doors today! Don’t miss our posters in the Biomarkers in Tissue and Blood poster session on Tuesday, June 17 from 10.45 – 20.00. Visit Booth 20 to discuss your research. For Research Use Only. Not for Use In Diagnostic Procedures.

Patient advocates offer an important voice in patient care decisions and Stephen Rowley is working to ensure they don’t go unheard. We're honoured to have Steve join our annual company Away Day next week, as he shares his thoughts on the future of cancer patient management.

Don’t miss David Greaves' poster session at #EACR2025!. Discover the ANGLE Portrait® AR Assay - an immunofluorescence-based assay that allows direct interrogation of AR in blood for minimally invasive monitoring of PCa patients. Request your 1:1 today:.

Attend Megan Coates' poster session at #EACR2025 to learn how detecting tumour mutations in liquid biopsies may provide a powerful and non-invasive tool for real-time monitoring of tumour dynamics. Request a 1:1 and join us at Booth 20

Next week we'll be attending #EACR2025 in Lisbon!. We're excited to join industry leaders and discuss the latest preclinical and translational cancer research; you can find us at Booth 20. Secure your 1:1 now:. We look forward to discussing your research!

We are proud to support World Brain Tumour Day 2025, Sunday, 8th June. This commemoration day is an annual tribute to all brain tumour patients and their families. The day is to spread awareness of causes and symptoms associated with brain tumours.